{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:19:00Z","timestamp":1783099140716,"version":"3.54.6"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031045","name":"Children&apos;s Health Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2018\/GNT1157287"],"award-info":[{"award-number":["2018\/GNT1157287"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.022","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:33:46Z","timestamp":1776944026000},"page":"534-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lumacaftor\u2013Ivacaftor in Pediatric Patients With Cystic Fibrosis and Advanced Liver Disease: A Pilot Study"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-4624","authenticated-orcid":false,"given":"Adeline Y.L.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Hern\u00e1ndez-Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lewindon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.022_bib0001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0002","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcf.2018.07.011","article-title":"Lumacaftor\/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1","volume":"18","author":"McColley","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0003","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jmr.2447","article-title":"Drug-drug plasma protein binding interactions of ivacaftor","volume":"28","author":"Schneider","year":"2015","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1872312812666180328105259","article-title":"Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor","volume":"12","author":"Schneider","year":"2018","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-023-01342-3","article-title":"Lumacaftor\/Ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis: a first step toward personalized therapy","volume":"63","author":"Bouazza","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0010","article-title":"Optimized LC-MS\/MS method for the high-throughput analysis of clinical samples of ivacaftor, its major metabolites, and lumacaftor in biological fluids of cystic fibrosis patients","volume":"128","author":"Schneider","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","article-title":"Hyperammonemia in review: pathophysiology, diagnosis, and treatment","volume":"27","author":"Auron","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0012","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Cystic fibrosis associated liver disease in children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0013","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/hep.1840160412","article-title":"Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study","volume":"16","author":"Colombo","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0014","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1055\/s-0039-1697591","article-title":"Gastrointestinal and hepatobiliary disease in cystic fibrosis","volume":"40","author":"Gabel","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0015","first-page":"1","article-title":"The pharmacokinetic changes in cystic fibrosis patients population: narrative review","volume":"12","author":"Awaness","year":"2024","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.clinthera.2026.03.022_bib0016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","article-title":"Pharmacokinetics of ivacaftor, tezacaftor, elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review","volume":"64","author":"Elzinga","year":"2025","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:31:18Z","timestamp":1783096278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000998"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lumacaftor\u2013Ivacaftor in Pediatric Patients With Cystic Fibrosis and Advanced Liver Disease: A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}